A compound of Formula (I) for energy storage,
A compound of Formula (I) for energy storage,
A compound of Formula (I) for energy storage,
wherein each of R5 and R6 is independently C1-6 alkyl, C1-6 alkoxy, halogen, trihalomethyl, or cyano; G is a C2-36 hydrocarbon, preferably a cyclic hydrocarbon; Q is —C(O)O—, —C(S)O—, —C(O)NH—, —C(O)S—, —C(S)NH—, —NHC(O)NH—, —NHC(S)NH—, or —C(O)NHC(O)—; X is a bond or a C1-30 straight- or branched-chain, saturated or unsaturated hydrocarbon;
A compound of Formula (I) for energy storage,
wherein each of R5 and R6 is independently C1-6 alkyl, C1-6 alkoxy, halogen, trihalomethyl, or cyano; G is a C2-36 hydrocarbon, preferably a cyclic hydrocarbon; Q is —C(O)O—, —C(S)O—, —C(O)NH—, —C(O)S—, —C(S)NH—, —NHC(O)NH—, —NHC(S)NH—, or —C(O)NHC(O)—; X is a bond or a C1-30 straight- or branched-chain, saturated or unsaturated hydrocarbon;
A compound of Formula (I) for energy storage,
wherein each of R5 and R6 is independently C1-6 alkyl, C1-6 alkoxy, halogen, trihalomethyl, or cyano; G is a C2-36 hydrocarbon, preferably a cyclic hydrocarbon; Q is —C(O)O—, —C(S)O—, —C(O)NH—, —C(O)S—, —C(S)NH—, —NHC(O)NH—, —NHC(S)NH—, or —C(O)NHC(O)—; X is a bond or a C1-30 straight- or branched-chain, saturated or unsaturated hydrocarbon;
are each independently aryl or heteroaryl 5- or 6-membered rings; each of R1, R2, R3, and R4 is in an ortho position to the azo group, and is independently halogen, C1-6 alkoxy, C1-6 alkylthio, halomethyl, dihalomethyl, trihalomethyl, or di(C1-6 alkyl)amino; r is 0 to 6; and p is 1 to 10, or 2 to 8, or 2 to 6, or 4 to 6, provided that r+p does not exceed the valence of G.
C07C 245/08 - Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
Described herein are compounds and methods for tethering proteins. For example, dimers of Protein X listed in Table 1 are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization and can be used to treat neurodegenerative diseases (such as, for example, Parkinson's Disease, ALS, Alzheimer's Disease, Huntington's Disease, Epilepsy, Frontotemporal Dementia, and/or DMD), cancer, autoimmune disease, and/or Celiac disease.
A compound of Formula (I)
A compound of Formula (I)
wherein in Formula (I), Ri1, Ri2, Ri3, and Ri4 are each independently an aryl or heteroaryl 5- or 6-membered ring optionally substituted with a C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, halogen, cyano, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, or di(C1-6 alkyl)amino; each L1, L2, L3, and L4 is independently a bond or a C1-30 linking group optionally including a heteroatom; CtS1 and CtS2 are each independently catalytic moieties; Z is a moiety that increases crystallinity of the compound; and r is 0 to 4, wherein a first geometric isomer of the compound of Formula (I) has a first solubility in the organic solvent, and a second geometric isomer of Formula (I) has a second, different solubility in the organic solvent. Use of the compound of Formula (I) as a homogenous organocatalyst, or as a photoswitchable, homogenous organocatalyst, or as a recyclable, photoswitchable, homogenous organocatalyst.
C07C 245/08 - Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
In one aspect, described is a method of selecting or identifying an agent that inhibits a target protein having an active site. In another aspect, described is a method of selecting an agent that inhibits a target protein having an active site for further optimization. In some embodiments, the methods include measuring or predicting stability of an induced fit conformation of an agent contacted to an active site of the protein, wherein the agent is selected if the stability of the induced fit conformation of the agent contacted to the active site of the protein is increased relative to a reference stability.
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
G16C 10/00 - Computational theoretical chemistry, i.e. ICT specially adapted for theoretical aspects of quantum chemistry, molecular mechanics, molecular dynamics or the like
6.
Tethering Cysteine Residues Using Cyclic Disulfides
Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including SOD1 and DJ-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization.
Described herein are steroid or steroid-like compounds including at least one isonitrile group and which inhibit the activity of a cytochrome P450 enzyme, as well as compositions including the compounds. Also included are methods of inhibiting activity of a cytochrome P450 in a subject having a steroid-responsive cancer, a Mycobacterium tuberculosis infection, a fungal infection, or a trypanosome infection, the method comprising administering to the subject the compound including at least one isonitrile group or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit the CYP activity in the subject.
C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The present invention relates to a peptide comprising D-amino acids. The D-amino acids include a plurality of aromatic amino acid residues, at least one amino acid residue having a neutral side chain, and a phosphorylated amino acid residue. The peptide further comprises an aromatic-containing group attached to the N-terminal end of the peptide. The present invention also relates to a cellular spheroid or organoid that is supported on or by a matrix formed by self-assembled peptides of the invention, as well as a method of inducing formation of a 3D cell spheroid. Methods of screening a drug are also described.
A method of treating a patient in need of chronic treatment for epilepsy or epileptogenesis includes chronically administering to the patient an extracellular Sema4D peptide which has at least 80%, 85%, 90%, 95%, 98% or 99% identity to amino acid residues 22 to 734 of SEQ ID NO: 1, amino acid residues 22-690- of SEQ ID NO: 3, or amino acid residues 22-733 of SEQ ID NO: 5, and wherein the chronic administration reduces the incidence of seizures in the patient, slows disease progression, and/or reduces the risk of death in the patient.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
An isolated peptide having the structure: where —NH-Q-C(O)— is an α-helical amino acid sequence that includes at least 4 and up to 30 amino acid residues, Z1 is a moiety including an aromatic group or a fluorophore, Z2 includes a phosphorylated amino acid residue, or the dephosphorylated amino acid residue. These peptides, in dephosphorylated form, are capable of self-assembly in the form of a nanoribbon, nanofiber, or a combination thereof. Such peptides are capable of causing cell death of cells that overexpress alkaline phosphatases, which includes cancer cells and induced pluripotent stem cells (iPSCs), and therefore the peptides of the invention can be used ex vivo to selectively cause cell death of cancer cells or iPSCs, or in vivo to cause cancer cell death.
An isolated peptide having the structure: where —NH-Q-C(O)— is an α-helical amino acid sequence that includes at least 4 and up to 30 amino acid residues, Z1 is a moiety including an aromatic group or a fluorophore, Z2 includes a phosphorylated amino acid residue, or the dephosphorylated amino acid residue. These peptides, in dephosphorylated form, are capable of self-assembly in the form of a nanoribbon, nanofiber, or a combination thereof. Such peptides are capable of causing cell death of cells that overexpress alkaline phosphatases, which includes cancer cells and induced pluripotent stem cells (iPSCs), and therefore the peptides of the invention can be used ex vivo to selectively cause cell death of cancer cells or iPSCs, or in vivo to cause cancer cell death.
The present invention relates to a compound of formula (I) or formula (II) as defined herein: Also disclosed are compositions that include compounds of formula (I) or formula (II) in an aqueous medium or a pharmaceutically acceptable carrier. Use of the compounds of formula (I) or formula (II) for delivering a drug moiety into the Golgi apparatus, imaging a cell, or treating a patient having a cancerous condition are also disclosed.
The Board of Trustees of the Leland Stanford Junior University Leland Stanford Junior University JUN (USA)
Inventor
Nakajima, Yuko
Haber, James E.
Jacobs-Wagner, Christine
Takacs, Constantin N.
Abstract
Described herein is a method of reducing virulence of a bacterial species with a segmented genome which has infected a mammalian host or mammalian host cell, by exposing the bacterial genome to an RNA-guided nuclease and a guide RNA (gRNA), thus generating a double-stranded or single-stranded break in the bacterial genome and causing loss of the targeted genome segment.
Glycosylated peptides and oligonucleotides of the invention contain oligosaccharides that include three or more saccharide moieties, wherein two saccharide moieties at a non-reducing terminal end of the oligosaccharide are coupled together with a thio-ether bond, and one of the saccharide moieties at a reducing end of the oligosaccharide is coupled to a reactive moiety. Also disclosed are immunogenic conjugates that include a glycopeptide or oligonucleotide bound to an immunogenic carrier molecule, as well as pharmaceutical compositions containing the same.
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
14.
BRANCHED PEPTIDES FOR ENZYMATIC ASSEMBLY AND MITOCHONDRIA DRUG DELIVERY
The present invention relates to a branched peptide that includes a first peptide chain and a second peptide chain having its C-terminal amino acid covalently linked to a sidechain of an amino acid residue of the first peptide chain, wherein the first peptide chain includes a plurality of aromatic amino acids and, optionally, an aromatic group linked to an amino terminus of the first peptide chain; and the second peptide chain includes a plurality of hydrophilic amino acids and an enzyme cleavage site. Pharmaceutical compositions containing the branched peptide and one or more therapeutic agents in an aqueous medium are disclosed, where the branched peptides form micelle structures in the aqueous medium. Methods of using the pharmaceutical composition to deliver therapeutic agents, and for treating various disease conditions are also described.
The present invention relates to a compound of Formula (I) where (II), (III), R1, R2, R3, R4, R5, Q, and Z are as described herein and compositions containing this compound. The present invention also relates to a methods of making a compound of Formula (I) and methods of using one or more of these compounds as a thermal-storage material thermal-storage device and. Methods of storing energy are also described.
The present invention relates to a compound of Formula (I) where (II), (III), R1, R2, R3, R4, R5, Q, and Z are as described herein and compositions containing this compound. The present invention also relates to a methods of making a compound of Formula (I) and methods of using one or more of these compounds as a thermal-storage material thermal-storage device and. Methods of storing energy are also described.
In accordance with some embodiments, systems, methods, and media for managing education processes in a distributed education environment are provided. In some embodiments, a system comprises at least one processor programmed to: receive information from multiple sources about a live educational process being experienced in a distributed education environment that facilitates real-time communication between an educator and students including at least audio communications; extract educational effectiveness indicators from at least the audio communications and an operation of the distributed education environment during the live educational process, including at least one of a number of audio communications, length of audio communications, or number of audio interactions by each student; access a database of demographic information about the students and correlate the demographic information with the students; and generate reports about individual students and groups within the students using the one or more educational effectiveness indicators and the demographic information.
G09B 5/14 - Electrically-operated educational appliances providing for individual presentation of information to a plurality of student stations with provision for individual teacher-student communication
A two-step process is provided for forming large photonic single crystals of about 0.1 millimeter and greater via DNA coated colloidal particles. The two-step process generally include decoupling the nucleation and growth steps. In particular, DNA colloidal particles are partitioned in nanoliter droplets formed in a water in oil emulsion using microfluidics. Once a crystal nucleates within a droplet, depletion of particles occurs as the crystal grows inhibit formation of more crystals within the droplet. A small number of droplets containing these seed crystals are then mixed with droplets containing weak DNA coated colloidal particles. The emulsion is then broken and heated at a temperature effective to cause dissociation of the weak particles while the seeds remain stable. The system is further cooled at a temperature effective that the particles stably adhere to the seed crystals resulting in growth while inhibiting nucleation of new crystals.
C30B 7/08 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
42 - Scientific, technological and industrial services, research and design
Goods & Services
Conducting surveys in the field of relational coordination downloadable surveys in the field of relational coordination Printed material, namely, surveys in the field of relational coordination Non downloadable surveys in the field of relational coordination
19.
THIOPHOSPHOPEPTIDES FOR ULTRAFAST TARGETING OF THE GOLGI APPARATUS
Disclosed are peptides having the structure according to formula (Ia) or (Ib) or (II): wherein NH-Q-C(O) is a peptide chain optionally comprising an amino acid residue having a sidechain covalently bonded to Z2; Z1 is a moiety comprising an aromatic group, a therapeutic agent, a fluorophore, or a nanoparticle; Z2 is H, a therapeutic agent, a fluorophore, or a nanoparticle; and J, if present (as in Ib or II), is a linker between the peptide chain and the thiophosphate group or thioester group. Also disclosed are pharmaceutical compositions that contain a peptide, as well as dephosphorylated peptides of the invention, which may take one or more forms include a nanofiber or a supramolecular hydrogel. Use of the peptides for delivering a therapeutic agent or drug moiety into the Golgi apparatus, imaging a cell, treating a patient having a cancerous condition, treating a patient having Alzheimer's or Parkinson's disease are also disclosed.
C07K 5/072 - Dipeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
C07K 5/107 - Tetrapeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
Microfluidic structures and methods for manipulating fluids and reactions are provided. Such structures and methods may involve positioning fluid samples, e.g., in the form of droplets, in a carrier fluid (e.g., an oil, which may be immiscible with the fluid sample) in predetermined regions in a microfluidic network. In some embodiments, positioning of the droplets can take place in the order in which they are introduced into the microfluidic network (e.g., sequentially) without significant physical contact between the droplets. Because of the little or no contact between the droplets, there may be little or no coalescence between the droplets. Accordingly, in some such embodiments, surfactants are not required in either the fluid sample or the carrier fluid to prevent coalescence of the droplets. Structures and methods described herein also enable droplets to be removed sequentially from the predetermined regions.
A substantially cylindrical glass bottle that is susceptible to accidental rolling and breakage when stored on its side has been structurally modified by forming a series of between approximately 8 and 24 small protrusions or bumpers spaced apart at regular intervals along either one path or two separated paths around the bottle's circumference at certain distances from the shoulder and base of the bottle. The bumpers project outward between approximately 2 mm to 6 mm from the bottle's outer sidewall surface, and pairs of these bumpers stably support the bottle stored on its side without the bottle rocking or rolling.
B65D 85/30 - Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
22.
FLEXIBLE ANTIVIRAL DNA ORIGAMI SHELLS THAT BLOCK INTERACTIONS BETWEEN VIRUS AND HOST CELLS
e.g.e.g., cylindrical, icosahedral, etc.) about the surface of a virus to encapsulate the virus, compositions comprising the nanostructures, and their use in treatment methods.
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
B82Y 40/00 - Manufacture or treatment of nanostructures
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
23.
PHOTOSWITCHABLE BINARY NANOPORE CAPABLE OF DETECTING SINGLE MOLECULES
University of Rhode Island Board of Trustees (USA)
Brandeis University (USA)
Inventor
Dwyer, Jason R
Hagan, James
Han, Grace G.D.
Gonzalez, Alejandra
Abstract
Disclosed herein is the fabrication of a photo-regulated nanopore by covalently linking a photoswitch to the interior of a silicon-based membrane and related methods of translocating an analyte and distinguishing molecule types through such a nanopore.
A method of making sterile diploid organisms includes mating a first population and a second population of single knock-in diploid organisms, wherein the first population of single knock-in diploid organisms are heterozygous organisms expressing a first marker inserted into a gene required for fertility, wherein the second population of single knock-in diploid organisms are heterozygous organisms expressing a second marker inserted into the gene required for fertility, wherein introduction of the first/second marker disrupts expression of the required fertility gene creating a first/second mutant allele of the gene required for fertility, and wherein the first and second markers are distinct; sorting offspring produced from the mating based on their expression of the first and/or second markers; and isolating the sterile diploid organisms, wherein the sterile diploid organisms are heteroallelic diploid organisms expressing the first marker in the first mutant allele and the second marker in the mutant second allele.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/90 - Stable introduction of foreign DNA into chromosome
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
25.
MANIPULATION OF FLUIDS, FLUID COMPONENTS AND REACTIONS IN MICROFLUIDIC SYSTEMS
Microfluidic structures and methods for manipulating fluids, fluid components, and reactions are provided. In one aspect, such structures and methods can allow production of droplets of a precise volume, which can be stored/maintained at precise regions of the device. In another aspect, microfluidic structures and methods described herein are designed for containing and positioning components in an arrangement such that the components can be manipulated and then tracked even after manipulation. For example, cells may be constrained in an arrangement in microfluidic structures described herein to facilitate tracking during their growth and/or after they multiply.
A tamper resistant hasp having: a first member extending between a first inner end and a first outer end, the first member defining a first member outer boundary and has a mounting aperture located within the first member outer boundary; a second member that has: a first portion that extends between a second inner end and a joint end, the second inner end being pivotally coupled to the first inner end, the second member pivots relative to the first member so that in a first pivot position the first portion is against the first member and covers the mounting aperture, and in a second pivot position such that the mounting aperture is uncovered; and a second portion that extends away from the first portion at the joint end to a third end and having a shackle aperture located within the second portion outer boundary.
A tamper resistant hasp having: a first member extending between a first inner end and a first outer end, the first member defining a first member outer boundary and has a mounting aperture located within the first member outer boundary; a second member that has: a first portion that extends between a second inner end and a joint end, the second inner end being pivotally coupled to the first inner end, the second member pivots relative to the first member so that in a first pivot position the first portion is against the first member and covers the mounting aperture, and in a second pivot position such that the mounting aperture is uncovered; and a second portion that extends away from the first portion at the joint end to a third end and having a shackle aperture located within the second portion outer boundary.
Described herein are compounds and methods for tethering proteins. For example, dimers of Protein X listed in Table 1 are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization and can be used to treat neurodegenerative diseases (such as, for example, Parkinson's Disease, ALS, Alzheimer's Disease, Huntington's Disease, Epilepsy, Frontotemporal Dementia, and/or DMD), cancer, autoimmune disease, and/or Celiac disease.
The invention relates to a peptide comprising from 3 to 20 amino acids, including at least two aromatic amino acid residues, and an N-terminal phosphorylated aryl group, wherein upon exposure to an enzyme that hydrolyzes the phosphate group the peptide self-assembles to form nanofibrils and optionally nanoparticles. Also disclosed are self-assembled products formed following exposure of the phospho-aryl peptide to an enzyme that hydrolyzes the phosphate group, and pharmaceutical compositions that contain the phospho-aryl peptide. Methods of using the phospho-aryl peptide include a method for forming a nanofibril network on or near the surface of target cells, a method for collecting a target cell secretome, and a method for treating a cancerous condition.
Described herein is a method of determining a distribution and/or quantification of pleomorphic virus particles in a sample including detecting the pleomorphic virus particles, and determining, based on the detecting, the distribution and/or quantification of spherical virus particles and/or filamentous virus particles in the sample. Also included are methods of screening a test dmg including adding a test drug to a sample comprising pleomorphic virus particles and detecting the distribution and/or quantification of spherical virus particles and/or filamentous virus particles in the sample containing the test drug.
G01N 15/02 - Investigating particle size or size distribution
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 15/06 - Investigating concentration of particle suspensions
32.
SELECTIVE ISONITRILE INHIBITORS OF CYTOCHROME P450 SUBTYPES
Described herein are steroid or steroid-like compounds including at least one isonitrile group and which inhibit the activity of a cytochrome P450 enzyme, as well as compositions including the compounds. Also included are methods of inhibiting activity of a cytochrome P450 in a subject having a steroid-responsive cancer, a Mycobacterium tuberculosis infection, a fungal infection, or a trypanosome infection, the method comprising administering to the subject the compound including at least one isonitrile group or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit the CYP activity in the subject.
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61P 31/06 - Antibacterial agents for tuberculosis
Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A01K 67/027 - New or modified breeds of vertebrates
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
34.
ARYLAZO-HETEROARYL COMPOUNDS AND THEIR USE FOR LONG-TERM THERMAL ENERGY STORAGE
IMPERIAL COLLEGE INNOVATIONS LIMITED (United Kingdom)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Han, Ggoch Ddeul
Gerkman, Mihael A.
Gibson, Rosina
Fuchter, Matthew J.
Grossman, Jeffrey C.
Abstract
The present invention relates to a compound of Formula (I): whereinR1, R2, m, n, p, Q, X, Y, W, and “A” are as described herein. The present invention also relates to a process for preparation of a compound of Formula (I). Also disclosed is a thermal-storage device comprising one or more compounds of Formula (I) and a method of storing energy.
The present invention features an antibody mimetic, or an antigen binding fragment thereof, that specifically binds to an allosteric site of Aurora A kinase, therapeutic compositions comprising this antibody mimetic, and the use of the monobody to modulate Aurora A kinase for the treatment of cancer.
The present invention features fusion polypeptides comprising an RNA binding polypeptide operationally linked to an RNA modifying enzyme (e.g., adenosine deaminase, cytidine deaminase), and methods of use therefore.
C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
Methods of improving mammalian carbohydrate metabolism and treating, preventing, or halting the progression of type 2 diabetes mellitus involve the consumption of a nutritional composition containing fruit or vegetable pomace. The pomace is produced from native plant tissue and contains a mixture of soluble and insoluble fiber. Periodic consumption of the composition normalizes blood glucose concentration and controls body weight.
The present disclosure relates to three-dimensional nucleic acid origami nanostructures that are designed to allow for self-assembly of the nanostructures into a larger structure (e.g., cylindrical, icosahedral, etc.) about the surface of a virus particle, and their use in treatment methods.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
The present disclosure relates to a conjugated prodrug comprising a peptide conjugated to an antibiotic molecules via a cleavable linker and pharmaceutical compositions thereof. Also disclosed are methods of enhancing the intracellular concentration of an antibiotic agent in a bacterium and methods of treating a patient for a bacterial infection.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present application discloses a method for selecting an RNA molecule that binds to a target molecule that includes providing a pool of oligonucleotide complexes, exposing the pool to a target molecule and allowing the second region of the RNA to bind a target molecule; and selecting from the pool one or more oligonucleotide complexes comprising an RNA molecule having the second region bound to the target molecule. Further disclosed is an isolated RNA molecule, an immunogenic conjugate, a pharmaceutical composition, a method of inducing an immune response in an individual, a method of inhibiting HIV-1 infection or proliferation, and a method for detecting a neutralizing antibody in serum.
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
42.
SULFUR-SUBSTITUTED SUGAR TO STABILIZE OLIGOSACCHARIDE
Glycosylated peptides and oligonucleotides of the invention contain oligosaccharides that include three or more saccharide moieties, wherein two saccharide moieties at a non-reducing terminal end of the oligosaccharide are coupled together with a thio-ether bond, and one of the saccharide moieties at a reducing end of the oligosaccharide is coupled to a reactive moiety. Also disclosed are immunogenic conjugates that include a glycopeptide or oligonucleotide bound to an immunogenic carrier molecule, as well as pharmaceutical compositions containing the same.
In accordance with some embodiments, systems, methods, and media for managing education processes in a distributed education environment are provided. In some embodiments, a system comprises at least one processor programmed to: receive information from multiple sources about a live educational process being experienced in a distributed education environment that facilitates real-time communication between an educator and students including at least audio communications; extract educational effectiveness indicators from at least the audio communications and an operation of the distributed education environment during the live educational process, including at least one of a number of audio communications, length of audio communications, or number of audio interactions by each student; access a database of demographic information about the students and correlate the demographic information with the students; and generate reports about individual students and groups within the students using the one or more educational effectiveness indicators and the demographic information.
G06Q 50/00 - Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
44.
THIOPHOSPHOPEPTIDES FOR ULTRAFAST TARGETING OF THE GOLGI APPARATUS
2122 is H, a therapeutic agent, a fluorophore, or a nanoparticle; and J, if present (as in lb or II), is a linker between the peptide chain and the thiophosphate group or thioester group. Also disclosed are pharmaceutical compositions that contain a peptide, as well as dephosphorylated peptides of the invention, which may take one or more forms include a nanofiber or a supramolecular hydrogel. Use of the peptides for delivering a therapeutic agent or drug moiety into the Golgi apparatus, imaging a cell, treating a patient having a cancerous condition, treating a patient having Alzheimer's or Parkinson's disease are also disclosed.
123455, Q, and Z are as described herein and compositions containing this compound. The present invention also relates to a methods of making a compound of Formula (I) and methods of using one or more of these compounds as a thermal-storage material thermal-storage device and. Methods of storing energy are also described.
F24D 11/00 - Central heating systems using heat accumulated in storage masses
F24D 11/02 - Central heating systems using heat accumulated in storage masses using heat pumps
F24H 7/04 - Storage heaters, i.e. heaters in which the energy is stored as heat in masses for subsequent release the released heat being conveyed to a transfer fluid with forced circulation of the transfer fluid
46.
LIGHT-RESPONSIVE TEMPORARY ADHESIVES AND USE THEREOF
The invention relates to a device that includes a substrate and a thin film of a photo-switchable adhesive layer applied to at least one surface of the substrate. A method of releasably supporting a product that includes adhering a product onto the thin film of the device and exposing the thin film to light sufficient to cause a change in the adhesive strength of the thin film. A method of making the device is also disclosed.
C09J 7/40 - Adhesives in the form of films or foils characterised by release liners
C09J 139/00 - Adhesives based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogenAdhesives based on derivatives of such polymers
47.
THERMAL STORAGE MATERIALS AND APPLICATIONS THEREOF
The present invention relates to automotive products, as well as uses thereof, which can facilitate warming of engine oil in an energy efficient and, therefore, more environmentally friendly manner. More specifically, a fluid reservoir is disclosed that includes a double walled vessel that defines a fluid containing compartment and has a self-contained region that shares a wall with the fluid containing compartment. A composition in the self-contained region at least partially covers the shared wall surface, and one or more light sources are positioned in the self-contained region to induce a phase change in the composition. The composition includes a phase-change material (PCM) and a molecular switch material. This fluid reservoir can be used to heat oil in an engine or oil pan.
Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including SOD1 and DJ-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization.
The present invention relates to a branched peptide that includes a first peptide chain and a second peptide chain having its C-terminal amino acid covalently linked to a sidechain of an amino acid residue of the first peptide chain, wherein the first peptide chain includes a plurality of aromatic amino acids and, optionally, an aromatic group linked to an amino terminus of the first peptide chain; and the second peptide chain includes a plurality of hydrophilic amino acids and an enzyme cleavage site. Pharmaceutical compositions containing the branched peptide and one or more therapeutic agents in an aqueous medium are disclosed, where the branched peptides form micelle structures in the aqueous medium. Methods of using the pharmaceutical composition to deliver therapeutic agents, and for treating various disease conditions are also described.
A method of making sterile diploid organisms includes mating a first population and a second population of single knock-in diploid organisms, wherein the first population of single knock-in diploid organisms are heterozygous organisms expressing a first marker inserted into a gene required for fertility, wherein the second population of single knock-in diploid organisms are heterozygous organisms expressing a second marker inserted into the gene required for fertility, wherein introduction of the first/second marker disrupts expression of the required fertility gene creating a first/second mutant allele of the gene required for fertility, and wherein the first and second markers are distinct; sorting offspring produced from the mating based on their expression of the first and/or second markers; and isolating the sterile diploid organisms, wherein the sterile diploid organisms are heteroallelic diploid organisms expressing the first marker in the first mutant allele and the second marker in the mutant second allele.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
53.
MULTIVALENT GLYCOPEPTIDES THAT TIGHTLY BIND TO CARBOHYDRATE-BINDING MONOCLONAL ANTIBODY FAMILY PGT128
The invention relates to a glycopeptide that includes one or more modified amino acid residues having a sidechain comprising a monosaccharide or an oligosaccharide, wherein the glycopeptide binds specifically to a carbohydrate-binding monoclonal antibody from PGT128 family, preferably with an affinity of less than 100 nM. Immunogenic conjugates that include the glycopeptide, and pharmaceutical compositions that include the glycopeptide or the immunogenic conjugate are also disclosed. Various method of using the glycopeptides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral infection, treating a cancerous condition, and detecting a neutralizing antibody.
Systems and methods are provided for producing isolated microfluidic droplets. In one aspect, a microfluidic system comprises a droplet isolation device and an injection system. The droplet isolation device includes at least one isolation unit and at least one capillary valve. The isolation unit has at least one chamber configured to receive at least two different aqueous solutions without mixing prior to entering the at least one chamber based at least in part on pressure levels of the at least two different aqueous solutions. The injection system includes an aqueous inlet, a non-aqueous inlet, a bypass outlet, a working fluid outlet, and a loading chamber. The injection system is configured to allow for a predetermined amount of each of the at least two different aqueous solutions to be delivered to the droplet isolation device sequentially.
IMPERIAL COLLEGE INNOVATIONS LIMITED (United Kingdom)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Han, Grace G.D.
Gerkman, Mihael A.
Fisher, Rosina
Fuchter, Matthew J.
Grossman, Jeffrey C.
Abstract
The present invention relates to a compound of Formula (I): wherein R1, R2, m, n, p, Q, X, Y, W, and "A" are as described herein. The present invention also relates to a process for preparation of a compound of Formula (I). Also disclosed is a thermal-storage device comprising one or more compounds of Formula (I) and a method of storing energy.
C07C 245/06 - Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
Microfluidic structures and methods for manipulating fluids, fluid components, and reactions are provided. In one aspect, such structures and methods can allow production of droplets of a precise volume, which can be stored/maintained at precise regions of the device. In another aspect, microfluidic structures and methods described herein are designed for containing and positioning components in an arrangement such that the components can be manipulated and then tracked even after manipulation. For example, cells may be constrained in an arrangement in microfluidic structures described herein to facilitate tracking during their growth and/or after they multiply.
Microfluidic devices and methods for investigating crystallization and/or for controlling a reaction or a phase transition are disclosed. In one embodiment, the microfluidic device includes a reservoir layer; a membrane disposed on the reservoir layer; a wetting control layer disposed on the membrane; and a storage layer disposed on the wetting control layer, wherein the wetting control layer and the storage layer define a microfluidic channel comprising an upstream portion, a downstream portion, a first fluid path in communication with the upstream and the downstream portions, and a storage well positioned within the first fluid path, wherein the wetting control layer includes a fluid passageway in communication with the storage well and the membrane, and wherein the wetting control layer wets a first fluid introduced into the microfluidic channel, the first fluid comprising a hydrophilic, lipophilic, fluorophilic or gas phase as the continuous phase in the microfluidic channel.
Disclosed are a peptide capable of induced self-assembly by a bioactive molecule comprising a (i) hydrogelation-promoting amino acid sequence and (ii) an oligomerization sequence; compositions containing the peptide and, optionally, bioactive molecule; hydrogels formed thereby; and various methods of using the same.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
59.
METHODS AND DEVICES FOR BIOCOMPATIBLE GLASS-BOTTOM MICROSCOPY CHAMBERS
A device for imaging sensitive biological samples is provided. The device can include a plastic frame and a glass coverslip, each can be comprised of a biologically compatible material. The device can then be configured such that a biological sample placed therein can only be in contact with biologically compatible materials and, when imaged, provide optimal imaging characteristics by allowing imaging through the glass coverslip.
The present disclosure relates to a conjugated prodrug comprising a peptide conjugated to an antibiotic molecules via a cleavable linker and pharmaceutical compositions thereof. Also disclosed are methods of enhancing the intracellular concentration of an antibiotic agent in a bacterium and methods of treating a patient for a bacterial infection.
An article comprising a substrate having a stimuli-responsive hydrogel polymer functionalized to or associated with a surface. The stimuli-responsive hydrogel polymer is at least partially hydrated by an aqueous disinfectant solution comprising a disinfectant. The disinfectant is formed-prior to hydrating the stimuli-responsive hydrogel polymer. At least a portion of the disinfectant is taken up, stored, or released as an aqueous solution or a gaseous vapor upon interaction with a stimulus.
D06M 13/00 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials with non-macromolecular organic compoundsSuch treatment combined with mechanical treatment
D06M 13/328 - Amines the amino group being bound to an acyclic or cycloaliphatic carbon atom
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
63.
LIGHT-RESPONSIVE TEMPORARY ADHESIVES AND USE THEREOF
The invention relates to a device that includes a substrate and a thin film of a photo-switchable adhesive layer applied to at least one surface of the substrate. A method of releasably supporting a product that includes adhering a product onto the thin film of the device and exposing the thin film to light sufficient to cause a change in the adhesive strength of the thin film. A method of making the device is also disclosed.
B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups
64.
THERMAL STORAGE MATERIALS AND APPLICATIONS THEREOF
The present invention relates to automotive products, as well as uses thereof, which can facilitate warming of engine oil in an energy efficient and, therefore, more environmentally friendly manner. More specifically, a fluid reservoir is disclosed that includes a double walled vessel that defines a fluid containing compartment and has a self-contained region that shares a wall with the fluid containing compartment. A composition in the self-contained region at least partially covers the shared wall surface, and one or more light sources are positioned in the self-contained region to induce a phase change in the composition. The composition includes a phase-change material (PCM) and a molecular switch material. This fluid reservoir can be used to heat oil in an engine or oil pan.
Microfluidic structures and methods for manipulating fluids, fluid components, and reactions are provided. In one aspect, such structures and methods can allow production of droplets of a precise volume, which can be stored/maintained at precise regions of the device. In another aspect, microfluidic structures and methods described herein are designed for containing and positioning components in an arrangement such that the components can be manipulated and then tracked even after manipulation. For example, cells may be constrained in an arrangement in microfluidic structures described herein to facilitate tracking during their growth and/or after they multiply.
The present invention relates to a branched peptide that includes a first peptide chain and a second peptide chain having its C-terminal amino acid covalently linked to a sidechain of an amino acid residue of the first peptide chain, wherein the first peptide chain includes a plurality of aromatic amino acids and, optionally, an aromatic group linked to an amino terminus of the first peptide chain; and the second peptide chain includes a plurality of hydrophilic amino acids and an enzyme cleavage site. Pharmaceutical compositions containing the branched peptide and one or more therapeutic agents in an aqueous medium are disclosed, where the branched peptides form micelle structures in the aqueous medium. Methods of using the pharmaceutical composition to deliver therapeutic agents, and for treating various disease conditions are also described.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
67.
Tethering cysteine residues using cyclic disulfides
Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including SOD1 and DJ-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization.
Methods of improving mammalian carbohydrate metabolism and treating, preventing, or halting the progression of type 2 diabetes mellitus involve the consumption of a nutritional composition containing fruit or vegetable pomace. The pomace is produced from native plant tissue and contains a mixture of soluble and insoluble fiber. Periodic consumption of the composition normalizes blood glucose concentration and controls body weight.
The present disclosure relates to multiplex production and phenotyping of genetically engineered cells using RNA-guided nucleases and genomic barcoding. In particular, high-throughput multiplex genome editing is achieved utilizing a system that facilitates precise genome editing at desired target chromosomal loci by homology directed repair. Integration of guide RNA and donor DNA sequences as a genomic barcode at a separate chromosomal locus allows identification, isolation, and massively-parallel validation of individual variants from a pool of transformants. Strains can be arrayed according to their precise genetic modifications, as specified by donor DNA incorporation in heterologous or native genes. The present disclosure further relates to a method of editing codons outside of canonical guide RNA recognition regions, which enables complete saturation mutagenesis of protein-coding genes, a marker-based internal cloning method, which removes background due to oligonucleotide synthesis errors and incomplete vector backbone cleavage, and a method of enhancing homology directed repair by active donor recruitment.
Microfluidic structures and methods for manipulating fluids and reactions are provided. Such structures and methods may involve positioning fluid samples, e.g., in the form of droplets, in a carrier fluid (e.g., an oil, which may be immiscible with the fluid sample) in predetermined regions in a microfluidic network. In some embodiments, positioning of the droplets can take place in the order in which they are introduced into the microfluidic network (e.g., sequentially) without significant physical contact between the droplets. Because of the little or no contact between the droplets, there may be little or no coalescence between the droplets. Accordingly, in some such embodiments, surfactants are not required in either the fluid sample or the carrier fluid to prevent coalescence of the droplets. Structures and methods described herein also enable droplets to be removed sequentially from the predetermined regions.
A microfluidic device comprising at least one isolation unit and at least one capillary valve. The at least one isolation unit has at least one chamber. The at least one chamber configured to receive at least two different aqueous solutions. The at least one capillary valve is configured to allow for the at least two different aqueous solutions to be introduced into the at least one chamber without mixing prior to entering the at least one chamber based at least in part on pressure levels of the at least two different aqueous solutions.
A composition and method for chlorine dioxide production through reaction-diffusion chemistry that facilitates the in situ generation of chlorine dioxide, wherein a dry solid composition of hydroxymethanesulfinic acid monosodium salt dihydrate (abbreviated HMS) and a chlorine dioxide precursor are activated via the addition or absorption of water to produce chlorine dioxide. The dry solid chemical composition comprises dry, safe, transportable reagents that integrate with polymeric materials such as packaging and superabsorbent and stimuli-responsive hydrogel polymers to combine with water to produce chlorine dioxide.
A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
A01N 35/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aliphatically bound aldehyde or keto groups, or thio-analogues thereofDerivatives thereof, e.g. acetals
A61L 15/18 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
A61L 15/20 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
A61L 15/46 - Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
73.
COMPOUNDS AND METHODS FOR TREATING CHRONIC MICROBIAL INFECTIONS
Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful for treating chronic bacterial infections. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention and a pharmaceutically acceptable excipient. Related methods of treating bacterial infections in mammals are disclosed. Moreover, the compounds may be used in combination with other therapeutic agents, such as antibacterial agents.
C07C 235/24 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07C 233/15 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
C07C 235/38 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
74.
Cinchonium betaine catalysts and methods of using same
C07D 453/04 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
C07C 249/02 - Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of compounds containing imino groups
C07B 57/00 - Separation of optically-active organic compounds
C07C 209/62 - Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C07D 453/00 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
75.
Multivalent glycopeptides that tightly bind to target proteins
The invention relates to a glycopolypeptide that includes one or more modified amino acid residues having a sidechain comprising a monosaccharide or an oligosaccharide, wherein the glycopolypeptide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nM. Immunogenic conjugates that include the glycopolypeptide, and pharmaceutical compositions that include the glycopolypeptide or the immunogenic conjugate are also disclosed. Various method of using the glycopolypeptides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral or bacterial infection, treating a cancerous condition, and detecting a neutralizing antibody.
In some embodiments, a system is provided, comprising: memory storing instructions that, when executed, cause a processor to: submit a first database query; receive a runtime to execute the first database query using a plan selected by a query optimizer; receive runtimes to execute the first database query using a plurality of test plans; determine, based on the runtimes, a metric indicative of the effectiveness of the query optimizer; and cause the metric indicative of the effectiveness of the query optimizer to be presented to a user.
Systems and methods are provided for producing isolated microfluidic droplets. In one aspect, a microfluidic system comprises a droplet isolation device and an injection system. The droplet isolation device includes at least one isolation unit and at least one capillary valve. The isolation unit has at least one chamber configured to receive at least two different aqueous solutions without mixing prior to entering the at least one chamber based at least in part on pressure levels of the at least two different aqueous solutions. The injection system includes an aqueous inlet, a non-aqueous inlet, a bypass outlet, a working fluid outlet, and a loading chamber. The injection system is configured to allow for a predetermined amount of each of the at least two different aqueous solutions to be delivered to the droplet isolation device sequentially.
Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 9/00 - Medicinal preparations characterised by special physical form
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
The invention relates to a glycopeptide that includes one or more modified amino acid residues having a sidechain comprising a monosaccharide or an oligosaccharide, wherein the glycopeptide binds specifically to a carbohydrate-binding monoclonal antibody from PGT128 family, preferably with an affinity of less than 100 nM. Immunogenic conjugates that include the glycopeptide, and pharmaceutical compositions that include the glycopeptide or the immunogenic conjugate are also disclosed. Various method of using the glycopeptides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral infection, treating a cancerous condition, and detecting a neutralizing antibody.
The invention relates to a method for selecting a glycopolypeptide that binds to a target protein, the method including the steps of providing a pool of glycopolypeptides fused via puromycin linker to an encoding mRNA-cDNA duplex; combining the pool with a target protein to form a mixture; incubating the mixture for a period of time sufficient to allow any target protein to bind to one or more of the glycopolypeptides, thereby forming glycopolypeptide-target protein complexes; and isolating from the mixture the glycopolypeptide-target protein complexes, thereby identifying a plurality of selected glycopolypeptides.
The method presented herein includes acquiring a mass spectrum of a molecule that includes mass spectrum peaks corresponding to a precursor ion and fragment ions. The method also includes identifying at least a portion of the fragment ions in the mass spectrum as corresponding to one or more monomer subunit ion of the precursor ion by appending one or more of the fragment ions to an inferable constituent to produce a topology building block. The topology building block is then stored in a candidate pool as corresponding to one or more of the monomer subunit ion if the combined mass of the inferable constituent and one or more of the fragment ions satisfy a first user-defined mass tolerance. One or more candidate topology of the precursor ion is then obtained by combining a plurality of the topology building blocks that satisfy a second user-defined mass tolerance for the precursor ion.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
H01J 49/00 - Particle spectrometers or separator tubes
H01J 49/26 - Mass spectrometers or separator tubes
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
An adjustable back brace configured to aid in the correction of spinal curvature during a treatment period of a patient is provided. In some aspects, the adjustable back brace comprises a rod, an inferior segment, and a superior segment. The inferior segment is configured to stabilize a pelvic region of the patient. The superior segment is configured to apply pressure to one of a first lateral side and a second lateral side of the patient, proximate a thoracic region of the patient to provide a corrective force on the spinal curvature of the patient. The superior segment is also selectively adjustable to be selectively moved and fixedly positioned in a plurality of positions along at least one of the lateral direction or the vertical direction, wherein the plurality of positions are designed for periodic adjustment of the corrective force on the spinal curvature during the treatment period.
A system and method for imaging a biological sample using a freezable fluid cell system is disclosed. The freezable fluid cell comprises a top chip, a bottom chip, and a spacer to control the thickness of a vitrified biological sample. The spacer is positioned between the top chip and the bottom chip to define a channel that is in fluid communication with an inlet port and an exit port to the freezable fluid cell system. The channel can be filled with a biological sample, vitrified, and imaged to produce high-resolution electron microscopic image.
H01J 37/20 - Means for supporting or positioning the object or the materialMeans for adjusting diaphragms or lenses associated with the support
G01N 1/42 - Low-temperature sample treatment, e.g. cryofixation
G01N 23/04 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material
G01N 23/225 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes
G01N 23/2204 - Specimen supports thereforSample conveying means therefor
G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]
The present invention includes certain conchinine-derived phase-transfer catalysts of formula (I), compositions comprising the same, and methods of promoting asymmetric addition reactions using the same.
C07D 453/04 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
Administration of a program for enabling participants to obtain discounts on products and services; Association services, namely, promoting the interests of alumni of a university; Providing employment counseling services; Providing employment information
87.
ENZYMATICALLY ACTIVATABLE PEPTIDE-REDOX MODULATOR CONJUGATES AND USE THEREOF
Disclosed are peptides capable of enzymatically-induced self-assembly to which is conjugated a redox modulator. These peptides are enzymatically responsive hydrogelators, and they can be used to form pericellular hydrogels/nanofibrils upon exposure to target cells that secrete or express a surface bound ectoenzyme having hydrolase activity suitable to induce peptide gelation. These materials, and compositions containing the same, can be used for inhibiting cancer cell migration, inhibiting cancer cell survival, and/or inhibiting cancer cell growth.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
C07K 5/107 - Tetrapeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
Microfluidic structures and methods for manipulating fluids, fluid components, and reactions are provided. In one aspect, such structures and methods can allow production of droplets of a precise volume, which can be stored/maintained at precise regions of the device. In another aspect, microfluidic structures and methods described herein are designed for containing and positioning components in an arrangement such that the components can be manipulated and then tracked even after manipulation. For example, cells may be constrained in an arrangement in microfluidic structures described herein to facilitate tracking during their growth and/or after they multiply.
The present invention is directed to the method for selecting an RNA molecule that binds to a target molecule and a kit for carrying out the method. This method includes: providing a pool of oligonucleotide complexes that each comprise a ds-DNA molecule and an RNA molecule, the ds-DNA molecule comprising a first DNA strand at least partially annealed to a first region of the RNA molecule, whereby a second region of the RNA molecule is free to adopt a secondary structure; exposing the pool to a target molecule and allowing the second region of the RNA to bind the target molecule; and selecting from the pool one or more oligonucleotide complexes comprising an RNA molecule having the second region bound to the target molecule.
The present invention features compositions comprising fusion polypeptides comprising an RNA binding polypeptide operationally linked to an RNA modifying enzyme (e.g., adenosine deaminase, cytidine deaminase), and methods of use therefore.
C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
The present invention relates to the use of DBH inhibitors (e.g., disulfiram and Nepicastat), and pharmaceutical compositions thereof, for treating subjects with certain types of memory loss, for instance memory loss associated with a neurodegenerative disease, disorder, or condition, such as Alzheimer's Disease.
A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
92.
High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
The invention relates to an oligonucleotide including one or more modified nucleoside bases having the structure -B-L-A wherein for each of the modified nucleosides A is independently a monosaccharide or oligosaccharide, Lisa linker molecule, and B is independently a pyrimidine or pyridine base linked to the sugar-phosphate backbone of the oligonucleotide; and wherein the oligonucleotide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nM. Immunogenic conjugates that include the oligonucleotide, and pharmaceutical compositions that include the oligonucleotide or the immunogenic conjugate are also disclosed. Various method of using the oligonucleotides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral or bacterial infection, treating a cancerous condition, and detecting a neutralizing antibody. A method is also disclosed for selecting the oligonucleotides using an alternative Selection of Modified Aptamers (SELMA).
C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Microfluidic devices and methods for investigating crystallization and/or for controlling a reaction or a phase transition are disclosed. In one embodiment, the microfluidic device includes a reservoir layer; a membrane disposed on the reservoir layer; a wetting control layer disposed on the membrane; and a storage layer disposed on the wetting control layer, wherein the wetting control layer and the storage layer define a microfluidic channel comprising an upstream portion, a downstream portion, a first fluid path in communication with the upstream and the downstream portions, and a storage well positioned within the first fluid path, wherein the wetting control layer includes a fluid passageway in communication with the storage well and the membrane, and wherein the wetting control layer wets a first fluid introduced into the microfluidic channel, the first fluid comprising a hydrophilic, lipophilic, fluorophilic or gas phase as the continuous phase in the microfluidic channel.
Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as antibacterial agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various infections in mammals, such as bacterial infections, are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
96.
COMPOSITIONS, METHODS, AND KITS FOR DETECTING AND IDENTIFYING MYCOBACTERIA
Provided herein are methods for detecting and identifying strains of mycobacteria, and compositions and kits for performing such methods. In particular, nucleic acid amplification and fluorescence detection methods are provided for the detection and differentiation of mycobacteria based on, for example, pathogenicity, species, and antibiotic resistance or sensitivity. Compositions and methods are provided herein to identify and differentiate mycobacteria in mixtures of different mycobacteria and mycobacteria and non-mycobacteria.
C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
97.
Manipulation of fluids, fluid components and reactions in microfluidic systems
Microfluidic structures and methods for manipulating fluids, fluid components, and reactions are provided. In one aspect, such structures and methods can allow production of droplets of a precise volume, which can be stored/maintained at precise regions of the device. In another aspect, microfluidic structures and methods described herein are designed for containing and positioning components in an arrangement such that the components can be manipulated and then tracked even after manipulation. For example, cells may be constrained in an arrangement in microfluidic structures described herein to facilitate tracking during their growth and/or after they multiply.
2, Q, A, D, and n are as described herein. This invention also relates to a pharmaceutical composition including a pharmaceutically acceptable carrier and a conjugate of formula (I). This invention also relates to a method making a conjugate of formula (I), and the use of the conjugate for treating cancerous conditions, modulating cell membrane microheterogeneity, stimulating an immunoresponse, and forming a network on or near the inner or outer surface of target cells.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
99.
Systems and methods for surveying the sclera of the eye
Systems and methods for surveying the sclera are provided. In some aspects, a method for generating a design for a prosthetic lens for an eye of a subject includes arranging an eye of a subject at a distance from a plurality of illumination sources and a plurality of imaging devices, projecting light onto the eye of the subject using the illumination sources, acquiring image data of the eye of the subject and the light using the plurality of imaging devices, generating a three dimensional map of the eye, including the sclera, using the image data; and designing, using the three dimensional map of the eye for the lens that fits over a cornea of the eye to engage the sclera and form a fluid pocket between the prosthetic lens that surrounds the cornea.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/107 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining the shape or measuring the curvature of the cornea
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/14 - Arrangements specially adapted for eye photography
100.
Drip-free glass bottles having a circumferential channel and methods of making and using such bottles
Described herein is a glass bottle configured to improve the mechanics of liquid flow and prevent drip initiation. Additionally, the glass bottle eliminates dripping during pouring to enable drip-free pouring. The dripping is prevented over a full range of pouring angles, which vary depending on the amount of liquid held in the glass bottle. A method of making the glass bottle and a method of enabling drip-free pouring using the glass bottle are also disclosed.
B65D 47/40 - Closures with filling and discharging, or with discharging, devices with drip catchers or drip-preventing means
B65D 23/06 - Integral drip catchers or drip-preventing means
B65D 47/06 - Closures with discharging devices other than pumps with pouring spouts or tubesClosures with discharging devices other than pumps with discharge nozzles or passages
